180 Life Sciences Corp. (ATNF)


-0.02 (-1.83%)
Symbol ATNF
Price $1.07
Beta 0.349
Volume Avg. 0.27M
Market Cap 40.338M
Shares () -
52 Week Range 0.79-8.285
1y Target Est -
DCF Unlevered ATNF DCF ->
DCF Levered ATNF LDCF ->
ROE -8.54% Neutral
ROA -4.29% Neutral
Operating Margin -
Debt / Equity 45.89% Neutral
P/E -
P/B 0.86 Buy


Consensus EPS

Upgrades & Downgrades

Latest ATNF news

NASDAQ Capital Market

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.